Anti-Ado-trastuzumab emtansine-HER2 antibody (STJA0032514)
SPECIFICATIONS
ClonalityMonoclonal
HostHumanized
ConjugationUnconjugated
IsotypeIgG1
General Information
| Short Description | Humanized monoclonal anti-Ado-trastuzumab emtansine-HER2 for use in FUNC in Human samples. Datasheet included with dilution recommendations, and related reagents. |
| Applications | FUNC |
| Host | Humanized |
| Reactivity | Human |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Clonality | Monoclonal |
| Isotype | IgG1 |
| Conjugation | Unconjugated |
| Purification | Affinity Purified |
| Formulation | 0.01M PBS, pH 7.2 |
| Storage Instruction | This solution is stable for at least 4 weeks when stored at 2-8°C. For long term storage aseptically aliquot and store at –80°C. Avoid repeated freeze/thaw cycles. |
Target Information
Additional Info
| Background | Ado-trastuzumab emtansine is a HER2-targeted antibody-drug conjugate which contains the humanized anti-HER2 IgG1, trastuzumab, covalently linked to the microtubule inhibitory drug DM1 via the stable thioether linker MCC. Trastuzumab is produced by Chinese hamster ovary cells, and DM1-MCC are produced by chemical synthesis. Ado-trastuzumab emtansine contains an average of 3.5 DM1 molecules per antibody. |
Information sourced from Uniprot.org